CD16A binding proteins and use for the treatment of immune disorders
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Ling Huang, Hua Li, Nadine Tuaillon
Life of this patent
Estimating the term…
Abstract
CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
Claims18
An isolated anti-CD16A antibody comprising a VH domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:35, a CDR2 having the amino acid sequence of SEQ ID NO:39, and a CDR3 having the amino acid sequence of SEQ ID NO:59 and a VL domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:67, a CDR2 having the amino acid sequence of SEQ ID NO:75, and a CDR3 having the amino acid sequence of SEQ ID NO:88, wherein said CDRs have an amino acid substitution selected from the group consisting of, in the VH domain, M34V in CDR1;
- H50L in CDR2, W52F in CDR2, D54N in CDR2, N60S in CDR2, A62S in CDR2;
- W99Y in CDR3, A101D in CDR3, and in the VL domain, K24R in CDR1, A25S in CDR1, F32Y in CDR1, M33L in CDR1, N34A in CDR1, T50D, T50W or T50S in CDR2, T51A in CDR2, N53S in CDR2, E55A or E55Q in CDR2, S56T in CDR2;
- N92Y in CDR3, N93S in CDR3, and D94T in CDR3, which positions are according to the Kabat numbering scheme.
An isolated humanized anti-CD16A antibody comprising a heavy chain variable region having the sequence of SEQ ID NO:113 and a light chain variable region having the sequence of SEQ ID NO:96.
An isolated humanized anti-CD16A antibody comprising a VH CDR1 having the sequence of SEQ ID NO:35, a VH CDR2 having the sequence of SEQ ID NO:39, a VH CDR3 having the sequence of SEQ ID NO:59, and a VL domain having the amino acid sequence of SEQ ID NO:96.
An isolated humanized anti-CD16A antibody that comprises a VL domain having the amino acid sequence SEQ ID NO:96.
An isolated anti-CD16A antibody comprising a VH CDR1 having the sequence of SEQ ID NO:35, a VH CDR2 having the sequence of SEQ ID NO:39, a VH CDR3 having the sequence of SEQ ID NO:59, and a light chain having the amino acid sequence of SEQ ID NO:98.
An isolated humanized anti-CD16A antibody comprising a light chain having the amino acid sequence of SEQ ID NO:98 and a heavy chain having the amino acid sequence of SEQ ID NO:111.
Dependencies are inferred from the claim text.